Infliximab ELISA (mAb-based)
Enzyme immunoassay for the specific and quantitative determination of free Infliximab (Remicade®, Remsima®) in human serum and plasma.
The solid phase (MTP) is coated by a highly specific monoclonal antibody directed against Infliximab. Therefore any cross reactivity to the other therapeutical monoclonal antibodies is excluded.
Legal Status: CE-Mark
Intended Use: This kit has been developed for the measurement of drug levels in research and diagnostic uses. It is suitable for Therapeutical Drug Monitoring (TDM) purposes.
Quality Control Certificates
Remicade® is a trademark of Janssen Biotech, Inc./Merck & Co.
Remsima® is a trademark of CellTrion Inc.
The Kit at a glance:
|Required Volume (µL)||10|
|Incubation Time (min)||100|
|Sample||Serum or Plasma|
|Standard Range (ng/mL, 10x)||0-2000|
|Detection Limit (ng/mL)||5|
|Spike Recovery (%)||>95|
|Shelf Life (years)||2|